Industry News
Biotechnology Industry News
Italian pharma Alfasigma is…
Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA could approve in a couple of weeks.
After a tumultuous tenure marked…
After a tumultuous tenure marked by recent clashes with the biopharma industry, Vinay Prasad, M.D., will be departing his post as the FDA’s top regulator of vaccines and cell and gene therapies at the end
San Francisco venture capital firm…
San Francisco venture capital firm Breakout Ventures announced the close of a $114 million fund to support founder-led companies working at the nexus of science and artificial intelligence.
The FDA is ending a roughly…
The FDA is ending a roughly nine-month hiatus of drug-related advisory committee meetings, convening its first session of 2026 to scrutinize a pair of oncology applications from AstraZeneca.
The planned closure of Bio Palette…
The planned closure of Bio Palette has triggered the termination of a deal that gave Beam Therapeutics rights to base editing technology. Having prepared for that outcome, Beam has retained access to the technology under
After 27 years with Bavarian…
After 27 years with Bavarian Nordic, including 12 as CEO, Paul Chaplin is stepping down from the helm at the Danish vaccine maker and moving back to Australia. Under his leadership, Bavarian Nordic blossomed from
Zealand Pharma’s Roche-partnered…
Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at 42 weeks in a phase 2 obesity trial.
In a strikingly blunt briefing, a…
In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy for Huntington’s disease.
Merck KGaA is no longer pursuing…
Merck KGaA is no longer pursuing clinical-stage candidates obtained through its $3.9 billion acquisition of SpringWorks, which centered on approved drugs.
Flagship Pioneering-backed Alltrna…
Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people.
The back-and-forth between the FDA…
The back-and-forth between the FDA and gene therapy developer uniQure is getting messier, with an agency spokesperson now denying the biotech’s claims about a sham trial request for the rare Huntington’s disease.
Cardiovascular biotech Tenaya…
Cardiovascular biotech Tenaya Therapeutics has signed a research collaboration agreement with RNAi specialist Alnylam Pharmaceuticals in a deal that includes a $10 million upfront payment and much more in potential milestone payments for Tenaya if
The FDA has put a partial clinical…
The FDA has put a partial clinical hold on PepGen’s phase 2 muscle wasting trial after reviewing preclinical data, continuing the stop-start advance of the program. Guggenheim Securities analysts blamed the hold on an “understaffed
Venture capital firm Portal…
Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while also establishing a venture fund to support early-stage life sciences and biotech companies.
After steering positive key…
After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with fleshing out Pfizer’s $43 billion Seagen acquisition into an antibody-drug conjugate empire while accelerating a PD-1xVEGF bispecific
Roche is plugging 710 billion won…
Roche is plugging 710 billion won (about $484 million) into South Korea’s biopharma industry, with the goal of attracting global clinical trials to the East Asian nation.
Bayer has discontinued an…
Bayer has discontinued an early-stage clinical gene therapy for a rare genetic disorder in favor of a similar candidate.
UCB has entered the red-hot T-cell…
UCB has entered the red-hot T-cell engager space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate.
The cash will be spread across…
The cash will be spread across four years to fund development of the anti-TL1A antibody duvakitug.
Ono Pharmaceutical subsidiary…
Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its pipeline, citing strategic reasons unrelated to the asset’s safety or efficacy.